Glucocorticoids, which are well established to regulate body fat mass distribution, adipocyte lipolysis, hepatic gluconeogenesis, and hepatocyte VLDL secretion, are speculated to play a role in the pathology of metabolic syndrome. Recent focus has been on the activity of 11-hydroxysteroid dehydrogenase type 1 (11-HSD1), which is capable of regenerating, and thus amplifying, glucocorticoids in key metabolic tissues such as liver and adipose tissue. To determine the effects of global 11-HSD1 inhibition on metabolic syndrome risk factors, we subcutaneously injected Western-type diet-fed hyperlipidemic mice displaying either moderate or severe obesity (LDLR-/- and Agouti;LDLR-/-, respectively) with the nonselective 11-HSD inhibitor carbenoxolone for 4 weeks. Body composition throughout the study, end-point fasting plasma analyses, and extent of hepatic steatosis and atherosclerosis were assessed. This route of treatment led to high levels of carbenoxolone detected in liver and fat and resulted in decreased weight gain due to reduced body fat mass in both mouse models. However, only Agouti;LDLR-/- mice showed an effect of 11-HSD1 inhibition on fasting insulin and plasma lipids, coincident with a reduction in VLDL due to mildly increased VLDL clearance and dramatically decreased hepatic triglyceride production. Agouti;LDLR-/- mice also showed the greatest effect of the drug on reducing atherosclerotic lesion formation. These findings indicate that subcutaneous injection of an 11-HSD1 inhibitor allows for the targeting of the enzyme in not only liver, but also adipose tissue and attenuates many metabolic syndrome risk factors, with more pronounced effects in cases of severe obesity and hyperlipidemia.